Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Abhydrolase domain-containing protein 17A (ABHD17A)
- Target
- ABHD17A
- Molecular classification
- Enzyme, Palmitoyl-protein thioesterase, Protein depalmitoylase, Alpha/beta hydrolase family
01
Overview
Abhydrolase domain-containing protein 17A (ABHD17A) is an enzyme of the alpha/beta hydrolase superfamily that functions as a protein depalmitoylase, hydrolyzing palmitate groups from S-acylated cysteine residues. ABHD17A is membrane-associated due to a palmitoylated N-terminal cysteine cluster and acts on various substrates including N-Ras, PSD95, and particular domains of ion channels such as the BK channel. Its activity regulates protein localization, influences signal transduction, and contributes to dynamic cellular processes such as the assembly of the NLRP3 inflammasome. ABHD17A has been implicated in neurological disorders and may play a modulatory role in oncogenic signaling through its regulation of protein palmitoylation and trafficking[1][2][3][4].
- Other names
- Alpha/beta hydrolase domain-containing protein 17AC19orf27FAM108A1MGC5244protein ABHD17AAB17A
02
Mechanism of action
Enzymatic hydrolysis (removes palmitate from S-acylated cysteine residues); Relocalization of membrane-associated proteins (like N-Ras, PSD95) by altering palmitoylation status
03
Biological functions
Protein depalmitoylationRegulation of protein localization to membranesRegulation of ion channel activityNegative regulation of NLRP3 inflammasome assembly
04
Disease associations
Neurodegenerative disease (e.g., Neuronal ceroid lipofuscinosis)Polyneuropathy (Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract)Cancer (through effects on N-Ras localization/signaling)
05
Safety considerations
No specific direct therapeutic safety concerns documented; potential off-target effects of inhibiting all protein depalmitoylation could impact signaling pathways and membrane protein localization[2][3].
06
Interacting drugs
None clearly established; generic palmitoylation inhibitors such as 2-bromopalmitate affect pathway but are not ABHD17A-specific[2][4].
07
Biomarkers
None specifically established for patient selection or monitoring
Beyond the preview
Go deeper on Abhydrolase domain-containing protein 17A (ABHD17A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abhydrolase domain-containing protein 17A (ABHD17A).